[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@kainvests Avatar @kainvests Kai invests

Kai invests posts on X about $iova, $nbis, saving, could you the most. They currently have XX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence finance stocks

Social topic influence $iova #3, $nbis #107, saving, could you, mckesson, all the, a very

Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA) Nebius Group N.V. Class A Ordinary Shares (NBIS) McKesson Corporation (MCK)

Top Social Posts #

Top posts by engagements in the last XX hours

"What's the difference between CAR-T and TIL therapies A video: A thread: #IOVA"
X Link @kainvests 2025-10-15T06:53Z XX followers, XXX engagements

"@newstart_2024 The company leading TIL therapy having saved so many lives and more to come: @IovanceBio Rooting on them by investing in them $IOVA"
X Link @kainvests 2025-10-13T10:34Z XX followers, XXX engagements

"$IOVA Iovance Biotherapeutics ($IOVA): Saving Lives on a Beautiful Hard-Fought Path"
X Link @kainvests 2025-10-08T08:04Z XX followers, XXX engagements

"#1 Most people focus on the complexity and cost of delivering a TIL solution and yet CAR-T has always been complex and expensive: CAR-T is also highly personalised and costs between $400000$700000 while TIL costs $500000. $IOVA"
X Link @kainvests 2025-10-15T06:54Z XX followers, XXX engagements

"$IOVA Most of us are biased toward a happy ending with Iovance. Shall we talk about whats likely to happen if the NSCLC data simply isnt good enough Do we foresee a dramatic dump and then a bump as happened with Replimune We need to be prepared for whatever happens"
X Link @kainvests 2025-10-14T19:26Z XX followers, XXX engagements

"The beauty of TIL therapy paradigm shift Guess whos leading it @IovanceBio $IOVA #TIL #TILTherapy #Cancer #FightCancer"
X Link @kainvests 2025-10-13T10:22Z XX followers, XXX engagements

"@TheRayMyers $NBIS and $IOVA; already have"
X Link @kainvests 2025-10-15T04:56Z XX followers, XXX engagements

"@BIOTECHSCANNER I'm curious why you lean toward a buyout rather than a partnership since everything seems to point toward the latter. Could you elaborate Thanks for everything :)"
X Link @kainvests 2025-10-13T21:04Z XX followers, XX engagements

"#4 CAR-T can't compete with TIL therapy for solid tumors. CAR-T dominate blood cancer (leukemia myeloma lymphoma etc) but don't work in solid tumors. CAR-T is a great example of a highly complex treatment becoming profitable over time"
X Link @kainvests 2025-10-15T07:21Z XX followers, XX engagements

"#5 TIL therapy true competitors are immune checkpoint inhibitors (the famous pembrolizumab) which are the 1st line standard and potentially TCR-T which are years behind compared to TIL. Notably Iovance is already working with Merck to combine pembrolizumab and TIL"
X Link @kainvests 2025-10-15T07:24Z XX followers, XX engagements

"$IOVA What's most likely: a BO or a partnership A partnership. Why Iovance is actively expanding commercial partnerships to increase patient access (e.g. with specialty pharmacies like Biologics by McKesson) and authorised treatment centres"
X Link @kainvests 2025-10-13T14:23Z XX followers, XXX engagements

"Hi @newstart_2024. I was very moved by your post on TIL therapy. Thanks for that. Many of us are investing in $IOVA to help make it happen and hopefully get some returns. I thought you may want to know of its existence and spread the word. We have binary catalysts coming"
X Link @kainvests 2025-10-14T07:06Z XX followers, XXX engagements

"@DeuceCabooseSki @pepemoonboy Iovance Biotherapeutics all the way $IOVA"
X Link @kainvests 2025-10-10T04:25Z XX followers, XXX engagements

"Are you in $NBIS but not in $IOVA You may want to look into it. 😉"
X Link @kainvests 2025-10-15T04:56Z XX followers, XXX engagements

"#6 And guess what Merck's key patents on Keytruda (pembrolizumab) are set to expire in 2028 but they will have exclusivity until 2030/2031. Merck here is a competitor but it has wisely also chosen to be an ally: these are TILVANCE-301 and IOV-COM-202. BO coming Partnership"
X Link @kainvests 2025-10-15T07:28Z XX followers, XX engagements

"@accounting_ds How low do we expect it to go Asking for a friend"
X Link @kainvests 2025-10-12T13:29Z XX followers, XX engagements

"$IOVA The most common days and times for Iovance to issue PRs based on topic"
X Link @kainvests 2025-10-10T08:33Z XX followers, XXX engagements

"$IOVA Iovance said at Wells Fargo that they will have a third party validate the NSCLC data. Someone made a very intelligent observation on StockTwits/IOVA yesterday. Why would they bother to have a third party validate bad data"
X Link @kainvests 2025-10-09T07:11Z XX followers, XXX engagements

"For $IOVA and $NBIS this is only the beginning"
X Link @kainvests 2025-10-13T07:34Z XX followers, XXX engagements

"@YodaStockInvest $IOVA in a few months and for a good cause 😉"
X Link @kainvests 2025-10-15T04:55Z XX followers, XXX engagements

"@DividendDude_X $NBIS $IOVA"
X Link @kainvests 2025-10-12T07:07Z XX followers, XXX engagements

"@TheRayMyers $IOVA"
X Link @kainvests 2025-10-10T11:59Z XX followers, XXX engagements